{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:01:44Z","timestamp":1784646104609,"version":"3.55.0"},"reference-count":28,"publisher":"Bioscientifica","issue":"3","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Levothyroxine titration is essential in low-risk differentiated thyroid cancer (DTC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare levothyroxine treatment adequacy, response distribution, and determinants of inadequacy in a large real-world cohort applying the 2015 versus 2025 American Thyroid Association (ATA) criteria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter, retrospective cohort study including 1,016 adults with low-risk DTC (median follow-up: 79 months). Dynamic risk stratification and levothyroxine treatment adequacy \u2013 defined according to framework-specific thyrotropin (TSH) targets \u2013 were assessed at 12 months and at the last visit. Secondary outcomes included rates of overtreatment and undertreatment. Multivariable logistic regression identified factors associated with adequacy among excellent or indeterminate responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Under the ATA-2025 criteria, the proportion of patients with an excellent response increased to 72.0% at 12 months and 86.9% at last visit, compared with 62.3 and 77.8% using the ATA-2015 criteria. Treatment adequacy changed from 26.0% at 12 months and 39.6% at the last follow-up visit with ATA-2015 to 40.7 and 67.4% with ATA-2025 (both P &amp;lt; 0.001). Under ATA-2015, inadequacy was driven by overtreatment among excellent responders (61.8% at 12 months; 30.5% at final evaluation) and undertreatment among indeterminate responders (48.4%; 62.2%). Applying the ATA-2025 criteria reclassified overtreated excellent responders as 51.9 and 25.5% and undertreated indeterminate responders as 6.6 and 8.8%, respectively. At the last visit, older age modestly favored adequacy (OR: 1.02 per year, 1.00\u20131.03) and levothyroxine dose instability strongly predicted inadequacy (OR: 0.12 for adequacy, 0.08\u20130.16).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Applying the ATA-2025 criteria increases the proportion of patients classified as having adequate TSH control and decreases the proportion labeled as over- or undertreated under the 2015 framework, reflecting the broader, risk-adapted TSH targets introduced in 2025.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-26-0066","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:49:38Z","timestamp":1780336178000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":0,"title":["Improved adequacy of levothyroxine treatment in low-risk differentiated thyroid cancer using the 2025 ATA criteria: a multicenter real-world analysis of 1,016 patients"],"prefix":"10.1530","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-0694","authenticated-orcid":true,"given":"Juan J","family":"D\u00edez","sequence":"first","affiliation":[{"name":"1"},{"name":"2"},{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Anda","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Alcazar","sequence":"additional","affiliation":[{"name":"2"},{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0227-3566","authenticated-orcid":true,"given":"Juan C","family":"Galofr\u00e9","sequence":"additional","affiliation":[{"name":"6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Familiar","sequence":"additional","affiliation":[{"name":"7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda J","family":"Pamplona-Civera","sequence":"additional","affiliation":[{"name":"8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Gonz\u00e1lez-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"9"},{"name":"10"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Herrero-Ruiz","sequence":"additional","affiliation":[{"name":"11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda R","family":"Alhambra","sequence":"additional","affiliation":[{"name":"12"},{"name":"13"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"Planas","sequence":"additional","affiliation":[{"name":"14"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"S\u00e1nchez-Ragnarsson","sequence":"additional","affiliation":[{"name":"10"},{"name":"15"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s","family":"Mart\u00edn-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"16"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Rodriguez-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"16"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Mora","sequence":"additional","affiliation":[{"name":"17"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Orois","sequence":"additional","affiliation":[{"name":"17"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinaldo","family":"S\u00e1nchez-Barrera","sequence":"additional","affiliation":[{"name":"18"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sastre","sequence":"additional","affiliation":[{"name":"19"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"2026072110063516600_bib1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S2213-8587(24)00310-3","article-title":"Trends in incidence, metastasis, and mortality from thyroid cancer in the USA from 1975 to 2019: a population-based study of age, period, and cohort effects","volume":"13","author":"Chen","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026072110063516600_bib2","doi-asserted-by":"crossref","first-page":"R597","DOI":"10.1530\/ERC-19-0294","article-title":"An update on the management of low-risk differentiated thyroid cancer","volume":"26","author":"Lamartina","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"2026072110063516600_bib3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/thy.2023.0449","article-title":"All-cause and cause-specific mortality among low-risk differentiated thyroid cancer survivors in the United States","volume":"34","author":"Tran","year":"2024","journal-title":"Thyroid"},{"key":"2026072110063516600_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ecl.2018.10.008","article-title":"Thyroid hormone suppression therapy","volume":"48","author":"Biondi","year":"2019","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2026072110063516600_bib5","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41574-020-00448-z","article-title":"Current practice in patients with differentiated thyroid cancer","volume":"17","author":"Schlumberger","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"2026072110063516600_bib6","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1001\/jama.2023.19052","article-title":"Hyperthyroidism: a review","volume":"330","author":"Lee","year":"2023","journal-title":"JAMA"},{"key":"2026072110063516600_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2026072110063516600_bib8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid"},{"key":"2026072110063516600_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1652862","article-title":"Assessment of levothyroxine therapy adequacy in low-risk differentiated thyroid carcinoma: a multicenter cohort study","volume":"16","author":"D\u00edez","year":"2025","journal-title":"Front Endocrinol"},{"key":"2026072110063516600_bib10","first-page":"873","volume-title":"AJCC Cancer Staging Manual","author":"Tuttle","year":"2017","edition":"8th"},{"key":"2026072110063516600_bib11","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.3390\/cancers17243912","article-title":"When guidelines meet reality: the combined impact of assay variability and prescribing differences on TSH management in thyroid cancer","volume":"17","author":"Petranovi\u0107 Ov\u010dari\u010dek","year":"2025","journal-title":"Cancers"},{"key":"2026072110063516600_bib12","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1210\/clinem\/dgaf463","article-title":"TSH cutoffs and recurrence risk in differentiated thyroid carcinomas: a systematic review and meta-analysis","volume":"110","author":"Cho","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072110063516600_bib13","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1210\/clinem\/dgaf417","article-title":"Establishing the adequate levothyroxine dose after total thyroidectomy: a systematic review with meta-analysis","volume":"110","author":"Chiardi","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072110063516600_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7895","article-title":"The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study","volume":"345","author":"Selmer","year":"2012","journal-title":"BMJ"},{"key":"2026072110063516600_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1089\/thy.2014.0287","article-title":"Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma","volume":"25","author":"Wang","year":"2015","journal-title":"Thyroid"},{"key":"2026072110063516600_bib16","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1210\/jc.2017-01986","article-title":"High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma","volume":"103","author":"Mazziotti","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026072110063516600_bib17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1001\/archinternmed.2012.402","article-title":"Subclinical hyperthyroidism and the risk of coronary heart disease and mortality","volume":"172","author":"Collet","year":"2012","journal-title":"Arch Intern Med"},{"key":"2026072110063516600_bib18","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid cancer","volume":"401","author":"Chen","year":"2023","journal-title":"Lancet"},{"key":"2026072110063516600_bib19","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1177\/10507256251390877","article-title":"Executive summary of the 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Praw","year":"2025","journal-title":"Thyroid"},{"key":"2026072110063516600_bib20","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/jso.26983","article-title":"Quality of life following lobectomy versus total thyroidectomy is significantly related to hypothyroidism","volume":"126","author":"Yaniv","year":"2022","journal-title":"J Surg Oncol"},{"key":"2026072110063516600_bib21","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.endinu.2021.11.008","article-title":"Evolution of suppressing TSH therapy at diagnosis and in the long-term follow-up in a cohort of differentiated thyroid cancer","volume":"69","author":"D\u00edaz-Soto","year":"2022","journal-title":"Endocrinol Diabetes Nutr"},{"key":"2026072110063516600_bib22","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038290","article-title":"Clinical inertia in thyrotropin suppressive therapy for low-risk differentiated thyroid cancer: a real-world experience at an endocrine center in Bangkok","volume":"103","author":"Thewjitcharoen","year":"2024","journal-title":"Medicine"},{"key":"2026072110063516600_bib23","first-page":"901","article-title":"Current recommendations for levothyroxine treatment of differentiated thyroid cancer patients are not properly implemented in clinical practice","volume":"35","author":"Martins de Almeida","year":"2012","journal-title":"J Endocrinol Investig"},{"key":"2026072110063516600_bib24","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/cen.14787","article-title":"Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients","volume":"97","author":"Yavuz","year":"2022","journal-title":"Clin Endocrinol"},{"key":"2026072110063516600_bib25","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12902-021-00871-x","article-title":"A multicenter, prospective study to observe the initial management of patients with differentiated thyroid cancer in China (DTCC study)","volume":"21","author":"Ming","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"2026072110063516600_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12020-025-04223-w","article-title":"Tailoring TSH suppression in differentiated thyroid carcinoma: evidence, controversies, and future directions","volume":"89","author":"Song","year":"2025","journal-title":"Endocrine"},{"key":"2026072110063516600_bib27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/thy.2024.0330","article-title":"Association between serum thyrotropin and cancer recurrence in differentiated thyroid cancer: a population-based retrospective cohort study","volume":"35","author":"Qiang","year":"2025","journal-title":"Thyroid"},{"key":"2026072110063516600_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.surg.2024.07.057","article-title":"Dose-dependent relationship between levothyroxine and health-related quality of life in survivors of differentiated thyroid cancer","volume":"179","author":"Braafladt","year":"2025","journal-title":"Surgery"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/15\/3\/ETJ-26-0066.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/15\/3\/ETJ-26-0066.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-26-0066\/519888\/etj-26-0066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-26-0066\/519888\/etj-26-0066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T14:06:48Z","timestamp":1784642808000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/15\/3\/ETJ260066\/77567\/Improved-adequacy-of-levothyroxine-treatment-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-26-0066","relation":{},"ISSN":["2235-0802","2235-0640"],"issn-type":[{"value":"2235-0802","type":"electronic"},{"value":"2235-0640","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"ETJ260066"}}